plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014.

Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.